COVID-19 Severe Pneumonia Clinical Trial
Official title:
Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen
SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis. The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04369469 -
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
|
Phase 3 |